Overview

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not amenable to resection, transplant or other potentially curative therapy or (b) cancer metastatic to the liver.
Phase:
Phase 1
Details
Lead Sponsor:
Provectus Biopharmaceuticals, Inc.